Synthesis and pharmacological characterization of C4-disubstituted analogs of 1 S,2 S,5 R,6 S -2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: Identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures

Journal of Medicinal Chemistry

Volumn 58, Issue 4, 2015, Pages 1776-1794

  Monn, James A ^a   Prieto, Lourdes ^a   Taboada, Lorena ^a   Pedregal, Concepcion ^a   Hao, Junliang ^a   Reinhard, Matt R ^a   Henry, Steven S ^a   Goldsmith, Paul J ^a   Beadle, Christopher D ^a   Walton, Lesley ^a   Man, Teresa ^a   Rudyk, Helene ^a   Clark, Barry ^a   Tupper, David ^a   Baker, S Richard ^a   Lamas, Carlos ^a   Montero, Carlos ^a   Marcos, Alicia ^a   Blanco, Jaime ^a   Bures, Mark ^a   Clawson, David K ^a   Atwell, Shane ^a   Lu, Frances ^a   Wang, Jing ^a   Russell, Marijane ^a   Heinz, Beverly A ^a   Wang, Xushan ^a   Carter, Joan H ^a   Xiang, Chuanxi ^a   Catlow, John T ^a   Swanson, Steven ^a   Sanger, Helen ^a   Broad, Lisa M ^a   Johnson, Michael P ^a   Knopp, Kelly L ^a   Simmons, Rosa M A ^a   Johnson, Bryan G ^a   Shaw, David B ^a   McKinzie, David L ^a   more..

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 METHYLBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; 2 AMINOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE DERIVATIVE; 2 AMINOSPIRO(BICYCLO[3.1.0]HEXANE 4,1' CYCLOPROPANE) 2,6 DICARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; CYCLOPROPANE DERIVATIVE; EGLUMETAD; LY 2934747; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; UNCLASSIFIED DRUG; 2-AMINOSPIRO(BICYCLO(3.1.0)HEXANE-4,1′-CYCLOPROPANE)-2,6-DICARBOXYLIC ACID; BICYCLO COMPOUND; METABOTROPIC RECEPTOR; SPIRO COMPOUND;

AGONIST; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIASTEREOISOMER; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; RAT; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; AGONISTS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE; SPRAGUE DAWLEY RAT;

ANIMALS; BICYCLO COMPOUNDS; CRYSTALLOGRAPHY, X-RAY; HUMANS; MALE; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SPIRO COMPOUNDS;

EID: 84923882241     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501612y     Document Type: Article

References (55)

1. ONeill, M. J.; Fell, M. J.; Svensson, K. A.; Witkin, J. M.; Mitchell, S. N. Recent developments in metabotropic glutamate receptors as novel drug targets Drugs Future 2010, 35, 307-324
2. Niswender, C. M.; Conn, P. J. Metabotropic glutamate receptors: physiology, pharmacology, and disease Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295-322
3. Julio-Pieper, M.; Flor, P. J.; Dinan, T. G.; Cryan, J. F. Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues Pharmacol. Rev. 2011, 63, 35-58
4. Chaki, S. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia Eur. J. Pharmacol. 2010, 639, 59-66
5. Marek, G. J. Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition Eur. J. Pharmacol. 2010, 639, 81-90
6. Marek, G. J.; Kinon, B. J.; McKinzie, D. L.; Schkeryantz, J. M.; Monn, J. A. Metabotropic glutamate 2/3 receptor agonists and positive allosteric modulators of metabotropic glutamate receptor 2 as novel agents for the treatment of schizophrenia. In Targets and Emerging Therapies for Schizophrenia; Albert, J. S.; Wood, M. W., Eds.; John Wiley and Sons, Inc.: Hoboken, NJ, 2012; pp 143-185.
7. Sanacora, G.; Zarate, C. A.; Krystal, J. H.; Manji, H. K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders Nat. Rev. Drug Discovery 2008, 7, 426-437
8. Swanson, C. J.; Bures, M.; Johnson, M. P.; Linden, A.-M.; Monn, J. A.; Schoepp, D. D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders Nat. Rev. Drug Discovery 2005, 4, 131-144
9. Witkin, J. M.; Marek, G. J.; Johnson, B. G.; Schoepp, D. D. Metabotropic glutamate receptors in the control of mood disorders CNS Neurol. Disord.: Drug Targets 2007, 6, 87-100
10. Moussawi, K.; Kalivas, P. Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction Eur. J. Pharmacol. 2010, 639, 115-122
11. Simmons, R. M. A.; Webster, A. A.; Kalra, A. B.; Iyengar, S. Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats Pharmacol., Biochem. Behav. 2002, 73, 419-427
12. Du, J.; Zhou, S.; Carlton, S. M. Group II metabotropic glutamate receptor activation attenuates peripheral sensitization in inflammatory states Neuroscience 2008, 154, 754-766
13. Kingston, A. E.; ONeill, M. J.; Lam, A.; Bales, K. R.; Monn, J. A.; Schoepp, D. D. Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795 Eur. J. Pharmacol. 1999, 377, 155-165
14. Battaglia, G.; Busceti, C. L.; Pontarelli, F.; Biagioni, F.; Fornai, F.; Paparelli, A.; Bruno, V.; Ruggieri, S.; Nicoletti, F. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice Neuropharmacology 2003, 45, 155-166
15. Schiefer, J.; Sprunken, A.; Puls, C.; Luesse, H.-G.; Milkereit, A.; Milkereit, E.; Johann, V.; Kosinski, C. M. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntingtons disease Brain Res. 2004, 1019, 246-254
16. Garcia, B. G.; Neely, M. D.; Deutch, A. Y. Cortical regulation of striatal medium spiny neuron dendritic remodeling in Parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss Cereb. Cortex 2010, 20, 2423-2432
17. Durand, D.; Carniglia, L.; Caruso, C.; Lasaga, M. mGlu3 receptor and astrocytes: partners in neuroprotection Neuropharmacology 2013, 66, 1-11
18. Arcella, A.; Carpinelli, G.; Battaglia, G.; DOnofrio, M.; Santoro, F.; Ngomba, R. T.; Bruno, V.; Casolini, P.; Giangaspero, F.; Nicoletti, F. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo Neuro-Oncology 2005, 236-245
19. Ciceroni, C.; Arcella, A.; Mosillo, P.; Battaglia, G.; Mastrantoni, E.; Oliva, M. A.; Carpinelli, G.; Santoro, F.; Sale, P.; Ricci-Vitiani, L.; De Maria, R.; Pallini, R.; Giangaspero, F.; Nicoletti, F.; Melchiorri, D. Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells Neuropharmacology 2008, 55, 568-576
20. Gu, G.; Lorrain, D. S.; Wei, H.; Cole, R. L.; Zhang, X.; Daggett, L. P.; Schaffhauser, H.; Bristow, L. J.; Lechner, S. M. Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition Brain Res. 2008, 1197, 47-62
21. Tamaru, Y.; Nomura, S.; Mizuno, N.; Shigemoto, R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites Neuroscience 2001, 106, 481-503
22. Linden, A.-M.; Shannon, H.; Baez, M.; Yu, J. L.; Koester, A.; Schoepp, D. D. Anxiolytic-like activity of the mGlu2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice Psychopharmacology 2005, 179, 284-291
23. Spooren, W. P. J. M.; Gasparini, F.; van der Putten, H.; Koller, M.; Nakanishi, S.; Kuhn, R. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice Eur. J. Pharmacol. 2000, 397, R1-R2
24. Fell, M. J.; Svensson, K. A.; Johnson, B. G.; Schoepp, D. D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist(-)-(1 R, 4 S,5 S,6 S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) J. Pharmacol. Exp. Ther. 2008, 326, 209-217
25. Zammataro, M.; Chiechio, S.; Montana, M. C.; Traficante, A.; Copani, A.; Nicoletti, F.; Gereau, R. W. mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists Mol. Pain 2011, 7, 6-10
26. Corti, C.; Battaglia, G.; Molinaro, G.; Riozzi, B.; Pittaluga, A.; Corsi, M.; Mugnaini, M.; Nicoletti, F.; Bruno, V. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection J. Neurosci. 2007, 27, 8297-8308
27. Fraley, M. E. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia Expert Opin. Ther. Pat. 2009, 19, 1-17
28. Trabanco, A. A.; Cid, J. M.; Lavreysen, H.; MacDonald, G. J.; Tresadern, G. Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2 Curr. Med. Chem. 2011, 18, 47-68
29. Dominguez, C.; Prieto, L.; Valli, M. J.; Massey, S. M.; Bures, M.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Schoepp, D. D.; Monn, J. A. Methyl substitution of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist J. Med. Chem. 2005, 48, 3605-3612
30. Sanger, H.; Hanna, L.; Colvin, E. M.; Grubisha, O.; Ursu, D.; Heinz, B. A.; Findlay, J. D.; Vivier, R. G.; Sher, E.; Lodge, D.; Monn, J. A.; Broad, L. M. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical cultures using FLIPR Neuropharmacology 2013, 66, 264-273
31. Ceolin, L.; Kantamneni, S.; Barker, G. R. I.; Hanna, L.; Murray, L.; Warburton, E. C.; Robinson, E. S. J.; Monn, J. A.; Fitzjohn, S. M.; Gollingridge, G. L.; Bortolotto, Z. A.; Lodge, D. Study of novel selective mGlu2 agonist in the temproro-ammonic input to CA1 neurons reveals reduced mGlu2 expression in a Wistar substrain with an anxiety-like phenotype J. Neurosci. 2011, 31, 6721-6731
32. Hanna, L.; Ceolin, L.; Lucas, S.; Monn, J.; Johnson, B.; Collingridge, G.; Bortolotto, Z.; Lodge, D. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist Neuropharmacology 2013, 66, 114-121
33. Lucas, S. J.; Bortolotto, Z. A.; Collingridge, G. L.; Lodge, D. Selective activation of either mGlu2 or mGlu3 receptors can induce LTD in the amygdala Neuropharmacology 2013, 66, 196-201
34. Monn, J. A.; Valli, M. J.; Massey, S. M.; Hao, J.; Reinhard, M.; Bures, M. G.; Heinz, B.; Wang, X.; Carter, J. H.; Getman, B. G.; Stephenson, G. A.; Herin, M.; Catlow, J. T.; Swanson, S.; Johnson, B. G.; Henry, S. S. Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists J. Med. Chem. 2013, 56, 4442-2255
35. Baker, S. R.; Beadle, C. D.; Clark, B. P.; Monn, J. A.; Prieto, L. MGlu 2/3 agonists. U.S. Pat. Appl. 2013/0197079, August 1, 2013.
36. Domínguez, C.; Ezquerra, J.; Prieto, L.; Espada, M.; Pedregal, C. Asymmetric synthesis of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740) Tetrahedron: Asymmetry 1997, 8, 511-514
37. Caglioti, L. Reduction of ketones by use of the tosylhydrazone derivatives: androstan-17 β-ol Org. Synth. 1972, 52, 122
38. Kuo, F.; Kulanthaivel, P.; Rener, G. A.; Wheeler, W. J.; Yi, P. 1. Synthesis of LY455169-[2H2], a model study for the tritium labeling of LY459477. 2. Synthesis of LY459477-[3H2]. In Synthesis and Applications of Isotopically Labeled Compounds, Proceedings of the International Symposium, Vol. 8; Dean, D. C.; Filer, C. N.; McCarthy, K. E., Eds.; John Wiley and Sons, Ltd.: Chichester, U.K., 2003; pp 267-270.
39. Wright, R. A.; Johnson, B. G.; Zhang, C.; Salhoff, C.; Kingston, A. E.; Calligaro, D. O.; Monn, J. A.; Schoepp, D. D.; Marek, G. J. CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [3H]LY459477 autoradiography Neuropharmacology 2013, 66, 89-98
40. Johnson, B. G.; Wright, R. A.; Arnold, M. B.; Wheeler, W. J.; Ornstein, P. L.; Schoepp, D. D. [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells Neuropharmacology 1999, 38, 1519-1529
41. Muto, T.; Tsuchiya, D.; Morikawa, K.; Jingami, H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 3759-3764
42. Wernimont, A. K.; Dong, A.; Seitova, A.; Crombet, L.; Khutoreskaya, G.; Edwards, A. M.; Arrowsmith, C. H.; Bountra, C.; Weigelt, J.; Cossar, D.; Dobrovetsky, E. Crystal structure of metabotropic glutamate receptor 3 precursor in presence of LY341495 antagonist. RCSB Protein Data Bank, deposited June 27, 2011; DOI: 10.2210/pdb3sm9/pdb.
43. Nishio, M. CH/pi hydrogen bonds in crystals CrystEngComm 2004, 6, 130-158
44. Salonen, L. M.; Ellermann, M.; Diederich, F. Aromatic rings in chemical and biological recognition: energetic and structures Angew. Chem., Int. Ed. 2011, 50, 4808-4842
45. Molecular Operating Environment (MOE), version 2013.08; Chemical Computing Group Inc. (1010 Sherbooke St. West, Suite No. 910, Montreal, QC, Canada, H3A 2R7), 2013.
46. Kleywegt, G. J.; Jones, T. A. Detecting folding motifs and similarities in protein structures Method. Enzymol. 1997, 277, 525-545
47. Monn, J. A.; Valli, M. J.; Massey, S. M.; Hansen, M. M.; Kress, T. J.; Wepsiec, J. P.; Harkness, A. R.; Grutsch, J. L., Jr.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A. E.; Tomlinson, R.; Lewis, R.; Griffey, K. R.; Tizzano, J. P.; Schoepp, D. D. Synthesis, pharmacological characterization and molecular modeling of heterobicyclic amino acids related to LY354740: identification of LY379268 and LY389795: two new potent, selective and systemically active agonists for group II metabotropic glutamate receptors J. Med. Chem. 1999, 42, 1027-1040
48. Dunkley, P. R.; Jarvie, P. E.; Robinson, P. J. A rapid Percoll gradient procedure for preparation of synaptosomes Nat. Protoc. 2008, 3, 1718-1728
49. Dunayevich, E.; Erickson, J.; Levine, L.; Landbloom, R.; Schoepp, D. D.; Tollefson, G. D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder Neuropsychopharmacology 2008, 33, 1603-1610
50. Monn, J. A.; Valli, M. J.; Massey, S. M.; Henry, S. S.; Stephenson, G. A.; Bures, M.; Herin, M.; Catlow, J.; Giera, D.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A. E.; Schoepp, D. D. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of LY389795: identification of potent, selective and orally bioavailable agonists for mGlu2/3 receptors J. Med. Chem. 2007, 50, 233-240
51. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Schoepp, D. D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat. Med. 2007, 13, 1102-1107
52. Kinon, B. J.; Gómez, J.-C. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia Neuropharmacology 2013, 66, 82-86
53. Kinon, B. J.; Millen, B. A.; Zhang, L.; McKinzie, D. L. Exploratory analysis for a targeted population responsive to the metabotropic glutamate 2/3 agonist pomaglumetad methionil in schizophrenia. Biol. Psychiatry 2015, submitted
54. Gilmour, G.; Broad, L. M.; Wafford, K. A.; Britton, T.; Colvin, E. M.; Fivush, A.; Gastambide, F.; Getman, B.; Heinz, B. A.; McCarthy, A. P.; Prieto, L.; Shanks, E.; Smith, J. W.; Taboada, L.; Edgar, D. M.; Tricklebank, M. D. In vitro characterization of the novel positive allosteric modulators of the mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architechture and operant responding in the rat Neuropharmacology 2013, 64, 224-239
55. Wu, S.; Wright, R. A.; Rockey, P. K.; Burgett, S. G.; Arnold, J. S.; Rosteck, P. R., Jr.; Johnson, B. G.; Schoepp, D. D.; Belagaje, R. Group III human metabotropic glutamate receptors 4, 7 and 8: "Molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells" Mol. Brain Res. 1998, 53, 88-97